AstraZeneca & Sputnik Light Joint Trial’s Preliminary Data Shows High Immunogenicity

Citing the preliminary data obtained during a clinical trial in Azerbaijan initiated in February 2021, the Russian Direct Investment Fund (RDIF) informed on Friday that AstraZeneca and Sputnik Light Covid-19 vaccines’ combo showed high immunogenicity, Business Standard reports.

The initial interim data analysis has previously demonstrated both vaccines can be safely combined without any serious adverse effects or post vaccination coronavirus infection, with preliminary data from the first 20 participants showing antibodies to the SARS-CoV-2 virus spike protein elicited in all cases.

A combination of AstraZeneca and the first component of Sputnik V, Sputnik Light, was tested based on mix and match approach, the premise that mixing of vaccines based on two different platforms could trigger a better immune response, also known as heterogeneous prime and boost.

Some experts believe that application of two different vaccines that use the same antigen as prime (first dose) and boost (second dose) can show better immune response.

Sputnik V developer Gamaleya Center, AstraZeneca, the RDIF and R-Pharm have signed cooperation memorandum in December 2020 framing the cooperation in the development and implementation of a clinical research program to evaluate the combined use of components of both vaccines.

Meanwhile, Indian regulator has approved a study that is combining the AstraZeneca’s jab made by Serum Institute of India called Covishield and Bharat Biotech’s vaccine Covaxin  led by Christian Medical College in Vellore.

Be the first to comment

Leave a Reply

Your email address will not be published.